Jeni’s Splendid Ice Creams has initiated a voluntary recall of a specific batch of its Passion Fruit Dreamsicle Ice Cream Bars due to concerns over undeclared ingredients. The announcement was made in compliance with guidelines set forth by the U.S. Food and Drug Administration (FDA), which is urging consumers with allergies to proceed with caution.
The recall affects a limited number of ice cream bars that may contain wheat and soy, neither of which were listed on the product packaging. Individuals with allergies or severe sensitivities to these ingredients face the risk of serious or potentially life-threatening allergic reactions if they consume the affected products.
Details of the Recall
The specific batch involved in the recall was distributed to retailers nationwide in the United States. Consumers are advised to check their freezers for the Passion Fruit Dreamsicle Ice Cream Bars, which are sold in boxes of four. The product in question has a specific lot number that is being communicated through various channels to ensure consumer safety.
In a statement, Jeni’s Splendid Ice Creams expressed regret over the oversight and emphasized its commitment to product safety. The company has urged anyone who has purchased the affected bars to return them to their point of purchase for a full refund.
Consumer Safety Measures
The FDA advises customers who have consumed the recalled product and are experiencing allergic reactions to seek immediate medical attention. Symptoms of an allergic reaction can include hives, difficulty breathing, and swelling of the face, lips, or throat.
As a precautionary measure, Jeni’s Splendid Ice Creams is implementing additional checks to prevent future occurrences of undeclared ingredients in its products. The company aims to reinforce its quality control processes, ensuring that all packaging accurately reflects the ingredients contained within.
This recall serves as a reminder for consumers to remain vigilant about checking product labels, especially if they have known food allergies. The FDA continues to monitor the situation and will provide updates as necessary.
